Aromatase inhibitor-related musculoskeletal symptoms: Is preventing osteoporosis the key to eliminating these symptoms?

Clinical Breast Cancer

Volumn 9, Issue 1, 2009, Pages 34-38

  Muslimani, Alaa ^a   Spiro, Timothy ^a   Chaudhry, Asif ^a   Taylor, Harris ^b   Do, Ishmael Jaiyesimi ^c   Daw, Hamed ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c William Beaumont Cancer Center   (United States)

Author keywords

Arthralgia; Bone mineral density; Calcium bisphosphonate; Tamoxifen

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; CALCIUM PHOSPHATE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY; PHOTON ABSORPTIOMETRY; RETROSPECTIVE STUDY;

ABSORPTIOMETRY, PHOTON; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CALCIUM PHOSPHATES; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 65649108908     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.006     Document Type: Article

References (38)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42.
2. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-606.
3. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-57.
4. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 259:2131-9.
5. Colozza M, Califano R, Minenza E, et al. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women. Mini Rev Med Chem 2008; 8:564-74.
6. Tḧrlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 2005; 353:2747-57.
7. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23:5138-47.
8. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
9. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.
10. Nordman IC, Spillane AJ, Hamilton AL. The aromatase inhibitors in early breast cancer: who, when, and why? Med J Aust 2005; 183:24-7.
11. Ohsako T, Inoue K, Nagamoto N, et al. Joint symptoms: a practical problem of anastrozole. Breast Cancer 2006; 13:284-8.
12. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16:223-34.
13. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007; 7:775-8.
14. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19:2767.
15. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006; 7:127-32.
16. Whannel KJ, Doughty JC, Wilson CR, et al. The effect of Aromatase inhibitors on bone mineral measured by serial DXA scans. ASCO annual meeting, 2007; 25(18S):(Abstract 11065).
17. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005; 97:1262-71.
18. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.
19. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
20. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-62.
21. Taylor M, Rastelli A, Civitelli R, et al. Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Twenty-seventh San Antonio Breast Cancer Symposium, 2004. Abstract 3072.
22. Dent S, DeValentin T, Vandermeer L, et al. Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Breast Cancer Res Treat 2006; 100(suppl 1):S190 (Abstract 4057).
23. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005; 9:2594-8.
24. Nevitt MC, Felson DT, Williams EN, et al. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: the Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2001; 44:811-8.
25. Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104:87-91.
26. Crew K, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25:3877-83.
27. Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41:346-52.
28. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 33:5305-12.
29. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-57.
30. Grumbach MM. Mutations in the synthesis and action of estrogen: the critical role in the male of estrogen on pubertal growth, skeletal maturation, and bone mass. Ann N Y Acad Sci 2004; 1038:7-13.
31. Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89:61-70.
32. Warr D, Johnston M, et al. Use of Bisphosphonates in Women with Breast Cancer. Practice Guide?ine. Toronto: Cancer Care Ontario, Program in Evidence-based Care; 2004 (Report 1-11).
33. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3:CD003474.
34. Boonen S, Haentjens P, Vandenput L, et al. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004; 255:1-12.
35. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26:1051-7.
36. Heshmati HM, Khosla S, Robins SP, et al. Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women. J Bone Miner Metab 1997; 12:S121 (Abstract 76).
37. Goss PE, Qi S, Cheung AM, et al. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004; 10:5717-23.
38. Goss PE, Hadji P, Subar M, et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007; 9:R52.